Kura Oncology (NASDAQ:KURA) Earns "Market Outperform" Rating from JMP Securities

JMP Securities reissued their market outperform rating on shares of Kura Oncology (NASDAQ:KURA - Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a $28.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on KURA. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Kura Oncology in a report on Monday, April 28th. Wall Street Zen downgraded shares of Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Kura Oncology in a report on Tuesday, April 8th. Cantor Fitzgerald upgraded Kura Oncology to a "strong-buy" rating in a research note on Tuesday, March 4th. Finally, Barclays cut their price objective on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Kura Oncology currently has an average rating of "Moderate Buy" and an average price target of $24.50.

Kura Oncology Stock Up 1.9%

NASDAQ:KURA traded up $0.12 during trading hours on Wednesday, hitting $6.57. 853,702 shares of the company's stock traded hands, compared to its average volume of 1,216,839. The stock's fifty day moving average price is $6.07 and its two-hundred day moving average price is $7.82. The firm has a market cap of $568.80 million, a P/E ratio of -2.78 and a beta of 0.50. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a twelve month low of $5.41 and a twelve month high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The company had revenue of $14.11 million for the quarter, compared to analysts' expectations of $39.08 million. On average, research analysts expect that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Virtus ETF Advisers LLC raised its holdings in shares of Kura Oncology by 71.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock worth $64,000 after buying an additional 3,061 shares in the last quarter. State of Wyoming acquired a new position in Kura Oncology during the first quarter worth $48,000. Harbor Advisors LLC bought a new position in shares of Kura Oncology during the fourth quarter valued at $87,000. Pallas Capital Advisors LLC acquired a new stake in shares of Kura Oncology in the 1st quarter valued at $66,000. Finally, E Fund Management Co. Ltd. bought a new stake in shares of Kura Oncology in the 4th quarter worth about $90,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.